首页> 外文期刊>Transplantation Proceedings >Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters.
【24h】

Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters.

机译:通过淋巴细胞药物敏感性和药代动力学参数评估肾移植中环孢素和他克莫司转化的最佳剂量和目标谷水平。

获取原文
获取原文并翻译 | 示例
           

摘要

We evaluated the relative clinical potency of cyclosporine (CyA) and tacrolimus (Tac) using pharmacodynamic and pharmacokinetic parameters of the drug to obtain the most suitable converting dose and target trough level. The relative pharmacodynamic potency was examined by the mean ratio of drug concentrations giving 50% inhibition of blastogenesis of lymphocytes (IC(50)) in 66 chronic renal failure patients. The relative potency estimated from clinical pharmacokinetic parameters was examined by the mean ratio of each pharmacokinetic parameter value of CyA versus Tac. The pharmacokinetic parameters were estimated by 12-hour monitoring of drug blood concentrations in seven CyA patients and seven Tac patients. The mean IC(50) ratio of CyA and Tac (CyA/Tac of IC(50)) was 25.1. The mean area under the concentration-time curve (AUC) ratio (CyA/Tac of AUC) was 25.5, the mean trough level (C(min)) ratio (CyA/Tac of C(min)) was 13.2, and the mean dose per body weight ratio was 25.2. The relative potency estimated from AUC that is the most reliable pharmacokinetic parameter for the estimation of clinical efficacy of calcineurin inhibitors appeared to agree with the relative pharmacodynamic potency estimated from IC(50). The data suggest that TAC 25-fold more potent than CyA, which represents a suitable converting dose ratio, and that target trough level of CyA is about 13-fold greater than Tac based on CyA/Tac of C(min). We conclude that these relative values may be useful to estimate the suitable dose and target trough levels to convert between CyA and Tac.
机译:我们使用药物的药效学和药代动力学参数评估了环孢素(CyA)和他克莫司(Tac)的相对临床效能,以获得最合适的转化剂量和目标谷水平。通过对66名慢性肾功能衰竭患者的淋巴细胞浓度(50%)产生抑制作用的平均药物浓度比(IC(50))检查相对药效学效力。根据临床药代动力学参数估算的相对效价通过CyA与Tac的每个药代动力学参数值的平均比值进行检验。通过对7位CyA患者和7位Tac患者的药物血药浓度进行12小时监测来估算药代动力学参数。 CyA和Tac的平均IC(50)比(IC(50)的CyA / Tac)为25.1。浓度-时间曲线(AUC)比(AUC的CyA / Tac)下的平均面积为25.5,平均谷值水平(C(min))比(CyA / Tac的C(min))下的平均面积为13.2,平均剂量/体重比为25.2。从AUC估计的相对效力是钙调神经磷酸酶抑制剂临床疗效评估中最可靠的药代动力学参数,似乎与从IC估计的相对药效效力一致(50)。数据表明,TAC的效价比CyA强25倍,这代表了合适的转化剂量比,并且基于C(最小)的CyA / Tac,CyA的目标谷值比Tac高约13倍。我们得出结论,这些相对值可能有助于估算合适的剂量和目标谷水平,以在CyA和Tac之间转换。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号